Literature DB >> 19003959

Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.

Martin Perez-Andres1, Julia Almeida, Marta Martin-Ayuso, Natalia De Las Heras, Maria Jesus Moro, Guillermo Martin-Nuñez, Josefina Galende, Rebeca Cuello, Isabel Abuín, Inmaculada Moreno, Mercedes Domínguez, Jose Hernandez, Gema Mateo, Jesus F San Miguel, Alberto Orfao.   

Abstract

Clonal plasma cells (PC) from different types of monoclonal gammopathies (MG) display distinct phenotypes consistent with an increased antigen-presentation and T-cell costimulation in MG of undetermined significance that deteriorates in malignant conditions. Expression of other cell surface and soluble molecules (e.g. adhesion/proliferation molecules) involved in the interaction between clonal PC and the bone marrow (BM) microenvironment has also been related to malignant PC, although the exact clinical significance of their expression remains largely unknown. Analysis of cell surface levels of several of these molecules in multiple myeloma (MM) patients shows an association between lower expression on BMPC of the HLA-I and beta2-microglobulin antigen-presenting molecules, the CD126 and CD130 IL6 receptor (IL6R) chains, and CD38, and adverse prognostic features of the disease. Likewise, patients showing higher soluble levels of antigen-presenting molecules (HLA-I and beta2-microglobulin), IL6R and CD95 tended to be associated with more aggressive disease behavior. In contrast, CD40, CD86, CD56, CD19, and CD45 were not associated with patients' outcome. Interestingly, upon considering the ratio between the soluble and PC membrane expression of each molecule, an increased adverse prognostic impact was observed for both HLA-I and beta2-microglobulin, but not for the other molecules. Multivariate analysis confirmed the independent prognostic value of cell surface expression of CD126 on BMPC together with serum beta2-microglobulin and LDH. In summary, our results show an abnormal distribution of the cellular and soluble compartments of the HLA-I, IL6R, and to a lower extent, CD95 molecules, in MM, associated with the clinical characteristics and behavior of the disease. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19003959     DOI: 10.1002/ijc.23941

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 2.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

3.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Authors:  P Arana; B Paiva; M-T Cedena; N Puig; L Cordon; M-B Vidriales; N C Gutierrez; F Chiodi; L Burgos; L-L Anglada; J Martinez-Lopez; M-T Hernandez; A-I Teruel; M Gironella; M-A Echeveste; L Rosiñol; R Martinez; A Oriol; J De la Rubia; A Orfao; J Blade; J-J Lahuerta; M-V Mateos; J-F San Miguel
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

Review 4.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

5.  Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Authors:  Katia Todoerti; Valentina Barbui; Olga Pedrini; Marta Lionetti; Gianluca Fossati; Paolo Mascagni; Alessandro Rambaldi; Antonino Neri; Martino Introna; Luigia Lombardi; Josée Golay
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

6.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

7.  Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Authors:  María V Martínez-Sánchez; Adela Periago; Isabel Legaz; Lourdes Gimeno; Anna Mrowiec; Natividad R Montes-Barqueros; José A Campillo; José M Bolarin; María V Bernardo; María R López-Álvarez; Consuelo González; María C García-Garay; Manuel Muro; Valentin Cabañas-Perianes; Jose L Fuster; Ana M García-Alonso; José M Moraleda; María R Álvarez-Lopez; Alfredo Minguela
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 8.  Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Authors:  Eyal Lebel; Boaz Nachmias; Marjorie Pick; Noa Gross Even-Zohar; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

Review 9.  Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.

Authors:  Andrew Paul; Joanne Edwards; Christopher Pepper; Simon Mackay
Journal:  Cells       Date:  2018-10-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.